A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis

Details for Australian Patent Application No. 2001288256 (hide)

Owner CardioVascular BioTherapeutics, Inc.

Inventors Kordyum, Vitaliy A.; Slavchenko, Iryna Yu; Chernykh, Svitlana I.; Vozianov, Oleksandr F.; Stegmann, Thomas J.

Agent Spruson & Ferguson

Pub. Number AU-B-2001288256

PCT Pub. Number WO02/14471

Priority 60/225,406 15.08.00 US

Filing date 15 August 2001

Wipo publication date 25 February 2002

Acceptance publication date 30 March 2006

International Classifications

C12P 21/00 (2006.01) Preparation of peptides or proteins

C07H 21/04 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C12N 1/21 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 7/00 (2006.01) Viruses, e.g. bacteriophages

C12N 15/70 (2006.01) Mutation or genetic engineering - Vectors or expression systems specially adapted for E. coli

Event Publications

30 March 2006 Application Accepted

  Published as AU-B-2001288256

4 May 2006 Assignment before Grant

  CardioVascular BioTherapeutics, Inc. The application has been assigned to CardioVascular BioTherapeutics, Inc.; Phage Biotechnology Corporation 2002

27 July 2006 Standard Patent Sealed

11 March 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

2 September 2010 Section 223 Application Received

  CardioVascular BioTherapeutics, Inc.; Phage Biotechnology Corporation An application to extend the time from 15 Aug 2009 to 15 Jun 2010 in which to pay the renewal fee has been filed . Address for service in Australia - FB Rice & Co Level 23 44 Market Street Sydney NSW 2000 2003

28 October 2010 Section 223 Application Allowed

  CardioVascular BioTherapeutics, Inc.; Phage Biotechnology Corporation The time in which to pay the renewal fee has been extended to 15 Jun 2010. Address for service in Australia - FB Rice & Co Level 23 44 Market Street Sydney NSW 2000 2003

9 December 2010 Assignment Registered

  Phage Biotechnology Corporation; CardioVascular BioTherapeutics, Inc. The patent has been assigned to New Technologies Holdings Pte Ltd

15 March 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001288257

2001288255